Search research articles
Contact Us
Filters
Showing results (131-140 of 167) with videos related to
Page
of 17
Sort By:
Cancer Discovery
|
November 30, 2018
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
Alexander Drilon, Siqing Fu, Manish R Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2020
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma
Leo I Gordon, Jason B Kaplan, Rakesh Popat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
George D Demetri, Filippo De Braud, Alexander Drilon, et al.
Nature
|
March 16, 2023
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Ghayas C Issa, Ibrahim Aldoss, John DiPersio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2025
Camizestrant in combination with three globally approved CDK4/6 inhibitors in women with ER+, HER2- advanced breast cancer: Results from SERENA-1
Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego, et al.
Oncotarget
|
January 26, 2023
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)
Leo I Gordon, Reem Karmali, Jason B Kaplan, et al.
Cancer Cell
|
November 14, 2018
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8<sup>+</sup> T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients
Aung Naing, Jeffrey R Infante, Kyriakos P Papadopoulos, et al.
The New England Journal of Medicine
|
August 23, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C Mutation
Adrian Sacher, Patricia LoRusso, Manish R Patel, et al.
Nature
|
December 2, 2005
A soft solid surface on Titan as revealed by the Huygens Surface Science Package
John C Zarnecki, Mark R Leese, Brijen Hathi, et al.
Blood
|
June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia
Eytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 167) with videos related to
Sort By:
Page
of 17
Cancer Discovery
|
November 30, 2018
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
Alexander Drilon, Siqing Fu, Manish R Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2020
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma
Leo I Gordon, Jason B Kaplan, Rakesh Popat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
George D Demetri, Filippo De Braud, Alexander Drilon, et al.
Nature
|
March 16, 2023
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Ghayas C Issa, Ibrahim Aldoss, John DiPersio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2025
Camizestrant in combination with three globally approved CDK4/6 inhibitors in women with ER+, HER2- advanced breast cancer: Results from SERENA-1
Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego, et al.
Oncotarget
|
January 26, 2023
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)
Leo I Gordon, Reem Karmali, Jason B Kaplan, et al.
Cancer Cell
|
November 14, 2018
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8<sup>+</sup> T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients
Aung Naing, Jeffrey R Infante, Kyriakos P Papadopoulos, et al.
The New England Journal of Medicine
|
August 23, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C Mutation
Adrian Sacher, Patricia LoRusso, Manish R Patel, et al.
Nature
|
December 2, 2005
A soft solid surface on Titan as revealed by the Huygens Surface Science Package
John C Zarnecki, Mark R Leese, Brijen Hathi, et al.
Blood
|
June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia
Eytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
Page
of 17